BioWorld

Oct. 30, 2009

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today) Read More

Transcept Plunges as FDA Cites Concerns About Insomnia Drug

Gene Fusions Are Not Random Events, but Aided by Hormones

Adjust-as-You-Go Trial Approach: Key to Pleasing FDA, Partners?

Aldagen Eyes Public Markets to Fund Two Phase III Efforts

Genta Crushed as Genasense Fails Another Phase III Study

Virdante Series A Brings in $47M to Boost New Antibody Program

Other News To Note

Clinic Roundup

Earnings Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...